[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.127.188. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
July 5, 2006

Varenicline for Smoking CessationDefinite Promise, But No Panacea

Author Affiliations
 

Author Affiliations: Department of Preventive Medicine, University of Tennessee Health Science Center (Drs Klesges, Johnson, and Somes); and Division of Epidemiology and Cancer Control, St Jude Children's Research Hospital (Dr Klesges), Memphis.

JAMA. 2006;296(1):94-95. doi:10.1001/jama.296.1.94

In this issue of JAMA, Gonzales and colleagues,1 Jorenby and colleagues,2 and Tonstad and colleagues3 report the results of 3 randomized trials on the efficacy of the nicotinic acetylcholine receptor partial agonist varenicline for achieving smoking cessation. For the clinician and the lay public, the major question from these trials is simply this: How effective and useful is varenicline for smoking cessation?

First Page Preview View Large
First page PDF preview
First page PDF preview
×